Commure
Total Raised
$813.89MInvestors Count
6Deal Terms
3Investments
2Funding, Valuation & Revenue
12 Fundings
Commure has raised $813.89M over 12 rounds.
Commure's latest funding round was a Series E for $70M on October 13, 2023.
Commure's valuation in September 2021 was $3,500M.
Commure's latest post-money valuation is from October 2023.
Sign up for a free demo to see Commure's valuations in October 2023 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/13/2023 | Series E | $70M | 3 | |||
1/19/2022 | Series D - II | $3.75M | 1 | |||
9/16/2021 | Series D | $250M | $3,500M | 2 | ||
8/18/2021 | Corporate Minority | |||||
11/19/2020 | Series C |
Date | 10/13/2023 | 1/19/2022 | 9/16/2021 | 8/18/2021 | 11/19/2020 |
|---|---|---|---|---|---|
Round | Series E | Series D - II | Series D | Corporate Minority | Series C |
Amount | $70M | $3.75M | $250M | ||
Investors | |||||
Valuation | $3,500M | ||||
Revenue | |||||
Sources | 3 | 1 | 2 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Commure Deal Terms
3 Deal Terms
Commure's deal structure is available for 3 funding rounds, including their Series E from October 13, 2023.
Round | Series E | Series D | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series E | |||||||||||||||
Series D | |||||||||||||||
Series A |
Commure Investors
6 Investors
Commure has 6 investors. General Catalyst invested in Commure's Series E funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/28/2017 | 10/13/2023 | 9 Seed VC, Series A (2018), Series B (2018), Series B - II (2019), Unattributed VC - II (2020), Series C (2020), Series D (2021), Series D - II (2022), Series E (2023) | Venture Capital | California | ||
Venture Capital | California | |||||
Corporation | Tennessee | |||||
Venture Capital | New York | |||||
Venture Capital | Texas |
First funding | 9/28/2017 | ||||
|---|---|---|---|---|---|
Last Funding | 10/13/2023 | ||||
Investor | |||||
Rounds | 9 Seed VC, Series A (2018), Series B (2018), Series B - II (2019), Unattributed VC - II (2020), Series C (2020), Series D (2021), Series D - II (2022), Series E (2023) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Corporation | Venture Capital | Venture Capital |
Location | California | California | Tennessee | New York | Texas |
Commure Acquisitions
6 Acquisitions
Commure acquired 6 companies. Their latest acquisition was Augmedix on July 19, 2024.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
7/19/2024 | Other Venture Capital | $106.8M | Acq - Pending | 3 | ||
10/31/2023 | Seed / Angel | |||||
10/4/2023 | Series B | |||||
8/18/2021 | Debt | |||||
3/15/2021 | Other |
Date | 7/19/2024 | 10/31/2023 | 10/4/2023 | 8/18/2021 | 3/15/2021 |
|---|---|---|---|---|---|
Investment Stage | Other Venture Capital | Seed / Angel | Series B | Debt | Other |
Companies | |||||
Valuation | |||||
Total Funding | $106.8M | ||||
Note | Acq - Pending | ||||
Sources | 3 |
Commure Investments
2 Investments
Commure has made 2 investments. Their latest investment was in Flexpa as part of their Seed VC on June 21, 2022.
Commure Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
6/21/2022 | Seed VC | Flexpa | $8.5M | Yes | 1 | |
4/14/2021 | Series A |
Date | 6/21/2022 | 4/14/2021 |
|---|---|---|
Round | Seed VC | Series A |
Company | Flexpa | |
Amount | $8.5M | |
New? | Yes | |
Co-Investors | ||
Sources | 1 |
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Commure to Competitors
iNTERFACEWARE specializes in healthcare data integration, providing solutions within the healthcare technology sector. The company offers the Iguana Integration Engine, a platform designed to connect electronic medical records (EMRs), electronic health records (EHRs), and various healthcare systems, devices, and applications, facilitating the exchange of healthcare data in multiple formats and protocols. iNTERFACEWARE primarily serves the healthcare industry, offering integration services, training, and resources to healthcare providers and software companies. It is based in Toronto, Ontario.
Eversolve specializes in application integration within the healthcare sector, focusing on interoperability and standard-based solutions. The company offers tools, services, and expertise to enable healthcare vendors and providers to integrate their applications and devices, ensuring efficient data exchange and communication. Eversolve primarily serves healthcare vendors, providers, and government agencies seeking to implement Electronic Health Record Systems and Personal Electronic Health Records. It is based in New Hampshire, United States.
Caristix is a company that focuses on healthcare IT, specifically in the domain of data flow and interoperability for hospitals and other healthcare partners. The company offers software solutions that automate tasks related to interoperability and data flow, such as scoping, testing, and maintenance, with the aim of simplifying the integration of complex IT systems in healthcare settings. The primary sectors that Caristix serves are the healthcare and IT industries. It is based in Quebec City, Quebec.
Linkmed specializes in healthcare information system integration. It focuses on interface solutions for the healthcare industry. It offers HL7 and DICOM interface software that enables seamless integration of medical devices and systems with healthcare information systems. It primarily serves the healthcare technology sector. It was founded in 2019 and is based in Boston, Massachusetts.
Redox offers an application program interface technology. It provides a modern application programming interface (API) for healthcare, allowing software to easily and securely interoperate with electronic health records (EHRs) in a health system infrastructure. The company offers various products such as Nova which has real-time data in the cloud, Chroma which patient identity records, and more. It was founded in 2014 and is based in Madison, Wisconsin.
Zus Health specializes in healthcare data interoperability. The company offers a shared health data platform that provides patient data at the point of care through application program interface (API), embedded components, and direct electronic health records (EHR) integrations. The platform is primarily used by healthcare organizations to understand patient history, streamline intake processes, and monitor patient medication adherence. It was formerly known as Zeus Healthcare Technologies. It was founded in 2020 and is based in Boston, Massachusetts.
Loading...